A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia

To facilitate the development of a prognostic model for early B-cell chronic lymphocytic leukemia (CLL), the Gruppo Italiano Malattie EMatologiche Maligne dell'Adulto (GIMEMA) proposes its multi-institutional effort as a working model. In total, 1138 newly diagnosed Binet stage A patients manag...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2005-04, Vol.46 (4), p.553-560
Main Authors: Molica, Stefano, Mauro, Francesca R, Callea, Vincenzo, Gentile, Massimo, Giannarelli, Diana, Lopez, Manuela, Lauria, Francesco, Rotoli, Bruno, Montanaro, Marco, Cortelezzi, Agostino, Liso, Vincenzo, Mandelli, Franco, Foa, Robin, on behalf of the GIMEMA CLL Study Group
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Cohort Studies
Disease Progression
Disease-Free Survival
Early CLL
Female
gender
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell - therapy
Male
Middle Aged
Multivariate Analysis
Predictive Value of Tests
Prognosis
Retrospective Studies
Risk Factors
Sex Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To facilitate the development of a prognostic model for early B-cell chronic lymphocytic leukemia (CLL), the Gruppo Italiano Malattie EMatologiche Maligne dell'Adulto (GIMEMA) proposes its multi-institutional effort as a working model. In total, 1138 newly diagnosed Binet stage A patients managed over the last 10 years outside the setting of clinical trials according to a "wait and see" policy form the basis of the present study aimed at investigating prognostic variables affecting disease progression, a surrogate endpoint for overall survival. A 3-stage risk system, simply obtained by summing the variables that proved significant in the multivariate analysis (i.e. short lymphocyte doubling time, advanced Rai substage, high peripheral blood lymphocytosis), is proposed. Clear-cut differences in the 10 year progression-free survival (PFS) were observed among patients scoring 0 (low risk), 1 (intermediate risk), 2-3 (high risk): 67.8, 41.0 and 24.8%, respectively (P
ISSN:1042-8194
1029-2403
DOI:10.1080/10428190400029965